At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 47 enrolled
Drug / intervention
Febuxostatdrug
Likely dose
Febuxostat 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Uric Acid With the Xanthine Oxidase Inhibitor Febuxostat: Effects on Blood Pressure, Metabolic Markers, and Aortic Stiffness in Prehypertensive
In Brief
A Phase 4 clinical trial evaluating Febuxostat for Prehypertension and 4 related conditions. Completed, enrolled 47 participants across 1 site.
Detailed Summary
High normal blood pressure, also called prehypertension, is a significant problem. High uric acid in the blood, the same thing that causes gout, may cause higher blood pressures. The investigators plan to monitor the effects of the drug febuxostat(trade name Uloric) on blood pressure and stiffness of the main blood vessels and see if lowering uric acid has any effect.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrehypertension, Gout, Pulse Wave Velocity, Hypertension, 24 Hour Blood Pressure
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedNov 2011
Primary CompletionMar 2014
TodayJul 2026
First PostedNov 16, 2011
Enrollment StartOct 1, 2011
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 14.6 years ago
Interventions
Febuxostatdrug
80mg PO daily for 8 weeks